dexmedetomidine has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Z; Huang, Y; Li, F; Zhan, H | 1 |
| Choi, YS; Hwang, HJ; Jun, JH; Oh, JE; Oh, YJ; Shin, EJ | 1 |
2 other study(ies) available for dexmedetomidine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Dexmedetomidine ameliorates diabetic cardiomyopathy by inhibiting ferroptosis through the Nrf2/GPX4 pathway.
Topics: bcl-2-Associated X Protein; Dexmedetomidine; Diabetes Mellitus; Diabetic Cardiomyopathies; Ferroptosis; Humans; Mannitol; NF-E2-Related Factor 2; Reactive Oxygen Species; Superoxide Dismutase | 2023 |
Dexmedetomidine restores autophagy and cardiac dysfunction in rats with streptozotocin-induced diabetes mellitus.
Topics: Animals; Autophagy; Cardiotonic Agents; Dexmedetomidine; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Heart; Heart Ventricles; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Streptozocin; Ventricular Function, Left | 2019 |